TY - JOUR
T1 - Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
AU - on behalf of the Dutch Pancreatic Cancer Group
AU - Groen, Jesse V.
AU - Douwes, Tom A.
AU - van Eycken, Elizabeth
AU - van der Geest, Lydia G. M.
AU - Johannesen, Tom B.
AU - Besselink, Marc G.
AU - Koerkamp, Bas Groot
AU - Wilmink, Johanna W.
AU - Bonsing, Bert A.
AU - Portielje, Johanna E. A.
AU - van de Velde, Cornelus J. H.
AU - Bastiaannet, Esther
AU - Mieog, J. Sven D.
N1 - Funding Information: Johanna W. Wilmink has received research funding from Servier, Halozyme, Novartis, Celgene, Astra Zeneca, Pfizer, Roche, Amgen, and Merck, and has served in a consulting or advisory role for Shire, Servier, and Celgene. The authors declare no conflicts of interest. Funding Information: EURECCA was funded by the European Society of Surgical Oncology. This work was supported by the Bas Mulder Award from the Alpe d’HuZes foundation/Dutch Cancer Society (UL2015-7665). The funding sources had no role in the study design; collection, analyses, or interpretation of the data; drafting of the manuscript; or the decision to publish. Funding Information: The authors thank the Belgian Cancer Registry (Brussels, Belgium) and the Cancer Registry of Norway (Oslo, Norway) for the collection of data; the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry; and IKNL staff for scientific advice. Publisher Copyright: © 2020, The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulting in a lack of evidence. Objective: The aim of this study was to compare treatment and overall survival (OS) of patients aged ≥ 70 years with stage I–II pancreatic cancer in the EURECCA Pancreas Consortium. Methods: This was an observational cohort study of the Belgian (BE), Dutch (NL), and Norwegian (NOR) cancer registries. The primary outcome was OS, while secondary outcomes were resection, 90-day mortality after resection, and (neo)adjuvant and palliative chemotherapy. Results: In total, 3624 patients were included. Resection (BE: 50.2%; NL: 36.2%; NOR: 41.3%; p < 0.001), use of (neo)adjuvant chemotherapy (BE: 55.9%; NL: 41.9%; NOR: 13.8%; p < 0.001), palliative chemotherapy (BE: 39.5%; NL: 6.0%; NOR: 15.7%; p < 0.001), and 90-day mortality differed (BE: 11.7%; NL: 8.0%; NOR: 5.2%; p < 0.001). Furthermore, median OS in patients with (BE: 17.4; NL: 15.9; NOR: 25.4 months; p < 0.001) and without resection (BE: 7.0; NL: 3.9; NOR: 6.5 months; p < 0.001) also differed. Conclusions: Differences were observed in treatment and OS in patients aged ≥ 70 years with stage I–II pancreatic cancer, between the population-based cancer registries. Future studies should focus on selection criteria for (non)surgical treatment in older patients so that clinicians can tailor treatment.
AB - Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulting in a lack of evidence. Objective: The aim of this study was to compare treatment and overall survival (OS) of patients aged ≥ 70 years with stage I–II pancreatic cancer in the EURECCA Pancreas Consortium. Methods: This was an observational cohort study of the Belgian (BE), Dutch (NL), and Norwegian (NOR) cancer registries. The primary outcome was OS, while secondary outcomes were resection, 90-day mortality after resection, and (neo)adjuvant and palliative chemotherapy. Results: In total, 3624 patients were included. Resection (BE: 50.2%; NL: 36.2%; NOR: 41.3%; p < 0.001), use of (neo)adjuvant chemotherapy (BE: 55.9%; NL: 41.9%; NOR: 13.8%; p < 0.001), palliative chemotherapy (BE: 39.5%; NL: 6.0%; NOR: 15.7%; p < 0.001), and 90-day mortality differed (BE: 11.7%; NL: 8.0%; NOR: 5.2%; p < 0.001). Furthermore, median OS in patients with (BE: 17.4; NL: 15.9; NOR: 25.4 months; p < 0.001) and without resection (BE: 7.0; NL: 3.9; NOR: 6.5 months; p < 0.001) also differed. Conclusions: Differences were observed in treatment and OS in patients aged ≥ 70 years with stage I–II pancreatic cancer, between the population-based cancer registries. Future studies should focus on selection criteria for (non)surgical treatment in older patients so that clinicians can tailor treatment.
UR - http://www.scopus.com/inward/record.url?scp=85084448477&partnerID=8YFLogxK
U2 - https://doi.org/10.1245/s10434-020-08539-x
DO - https://doi.org/10.1245/s10434-020-08539-x
M3 - Article
C2 - 32388741
SN - 1068-9265
VL - 27
SP - 5337
EP - 5346
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 13
ER -